WO2008010980A3 - Tat-049 and methods of assessing and treating cancer - Google Patents

Tat-049 and methods of assessing and treating cancer Download PDF

Info

Publication number
WO2008010980A3
WO2008010980A3 PCT/US2007/016113 US2007016113W WO2008010980A3 WO 2008010980 A3 WO2008010980 A3 WO 2008010980A3 US 2007016113 W US2007016113 W US 2007016113W WO 2008010980 A3 WO2008010980 A3 WO 2008010980A3
Authority
WO
WIPO (PCT)
Prior art keywords
tat
cancer
polypeptides
nucleic acids
antibodies
Prior art date
Application number
PCT/US2007/016113
Other languages
French (fr)
Other versions
WO2008010980A2 (en
Inventor
Daneil Chelsky
Patrice Hugo
Leslie H Kondejewski
Lyes Hamaidi
Joel Lanoix
Eustache Paramithiotis
Paul E Kearney
David Mcelligott
Scott R Peterson
Christopher Mark Hill
Original Assignee
Thallion Pharmaceuticals Inc
Daneil Chelsky
Patrice Hugo
Leslie H Kondejewski
Lyes Hamaidi
Joel Lanoix
Eustache Paramithiotis
Paul E Kearney
David Mcelligott
Scott R Peterson
Christopher Mark Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thallion Pharmaceuticals Inc, Daneil Chelsky, Patrice Hugo, Leslie H Kondejewski, Lyes Hamaidi, Joel Lanoix, Eustache Paramithiotis, Paul E Kearney, David Mcelligott, Scott R Peterson, Christopher Mark Hill filed Critical Thallion Pharmaceuticals Inc
Publication of WO2008010980A2 publication Critical patent/WO2008010980A2/en
Publication of WO2008010980A3 publication Critical patent/WO2008010980A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Surprisingly, the present inventors have discovered that expression of TAT- 049 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-049 is associated with abnormal development and growth. In addition, TAT-049 polypeptides, TAT-049 nucleic acids, and antibodies to TAT-049 have been generated. Accordingly, the present invention provides methods of diagnosising a TAT-049 associated disease such as cancer (e.g., lung cancer) using the TAT-049 polypeptides, TAT-049 nucleic acids, and antibodies to TAT-049 of the invention. Further, the TAT-049 polypeptides, TAT-049 nucleic acids, and antibodies to TAT-049 of the invention can be used to treat a animal suffering from a TAT-049 associated disease such as cancer (e.g., lung cancer). In other embodiments, TAT-049 polypeptides and TAT-049 nucleic acids can be used as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy and compounds that inhibit TAT-049 expression or activity.
PCT/US2007/016113 2006-07-14 2007-07-16 Tat-049 and methods of assessing and treating cancer WO2008010980A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83104806P 2006-07-14 2006-07-14
US60/831,048 2006-07-14

Publications (2)

Publication Number Publication Date
WO2008010980A2 WO2008010980A2 (en) 2008-01-24
WO2008010980A3 true WO2008010980A3 (en) 2008-08-28

Family

ID=38957301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016113 WO2008010980A2 (en) 2006-07-14 2007-07-16 Tat-049 and methods of assessing and treating cancer

Country Status (1)

Country Link
WO (1) WO2008010980A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034799A1 (en) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 6 human secreted proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034799A1 (en) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 6 human secreted proteins

Also Published As

Publication number Publication date
WO2008010980A2 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
Smart et al. The emerging role of TYRO3 as a therapeutic target in cancer
MX2010002716A (en) Neuroendocrine factors for treatment of degenerative diseases.
NZ591137A (en) Methods and systems for predicting response of cells to a therapeutic agent
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
MX2008009886A (en) Antibodies that bind par-2.
Ge et al. Senolytic targets and new strategies for clearing senescent cells
NO20056236L (en) Treatment with anti-VEGF antibodies
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
IS8432A (en) Antibodies that bind to leukocyte receptor-4
WO2007145840A3 (en) Compositions and methods for diagnosing and treating cancer
NO20092522L (en) Compositions and Methods for Treating Cancer with Cupredoxins and CPG Rich DNA
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
WO2005123760A3 (en) Treating cancer
EA201591219A1 (en) ANTIBODIES AGAINST LAMP1 AND CONJUGATES ANTIBODIES AND MEDICINES AND THEIR APPLICATION
MXPA05011085A (en) Compositions and methods relating to stop-1.
ATE506961T1 (en) CCN3 PROTEINS FOR THE TREATMENT AND DIAGNOSIS OF KIDNEY DISEASES
WO2009095452A8 (en) Crystal structure of the atpase domain of proteins of the hsp70 family
WO2006083957A3 (en) Tat-001 and methods of assessing and treating cancer
WO2008021896A3 (en) Therapeutic methods for neuropathic pain
WO2008010980A3 (en) Tat-049 and methods of assessing and treating cancer
WO2008013816A3 (en) Tat-051 and methods of assessing and treating cancer
EA200700346A1 (en) BACTERIOPHAG- AND PROFAG-SPECIFIC PROTEINS IN CANCER GENETIC THERAPY
WO2006133145A3 (en) Tat-007 and methods of assessing and treating cancer
WO2006116681A3 (en) Tat-003 and methods of assessing and treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07836082

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07836082

Country of ref document: EP

Kind code of ref document: A2